- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00385255
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
June 6, 2019 updated by: GlaxoSmithKline
A Study to Evaluate Immunogenicity and Safety of Boostrix When Co-administered With Fluarix in Subjects 19 Years of Age and Older
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years.
This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1726
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35802
- GSK Investigational Site
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- GSK Investigational Site
-
Mesa, Arizona, United States, 85213
- GSK Investigational Site
-
Phoenix, Arizona, United States, 85014
- GSK Investigational Site
-
-
Florida
-
Inverness, Florida, United States, 34452
- GSK Investigational Site
-
Melbourne, Florida, United States, 32935
- GSK Investigational Site
-
Pembroke Pines, Florida, United States, 33024
- GSK Investigational Site
-
-
Illinois
-
Peoria, Illinois, United States, 61602
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15217
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, United States, 15220
- GSK Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- GSK Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77024
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female adults aged between 19 to 64 years, inclusive for the primary cohort), or aged 65 years or older (for the exploratory cohort), at the time of vaccination.
Exclusion Criteria:
- Administration of an influenza vaccine within six months prior to study entry
- Administration of a diphtheria-tetanus (Td) booster within the previous 5 years.
- Administration of a Tdap vaccine at any time prior to study entry.
- Administration of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding vaccination, or planned use during the entire study period.
- History of diphtheria and/or tetanus and/or pertussis disease.
- History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphtheria toxoid or pertussis-containing vaccine or influenza vaccine or any component of the study vaccines.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BOOSTRIX+FLUARIX GROUP
Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
|
GSK Biologicals' inactivated influenza split virus vaccine.
GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
|
Experimental: FLUARIX BOOSTRIX GROUP
Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
|
GSK Biologicals' inactivated influenza split virus vaccine.
GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Toxoid Antigens
Time Frame: At Month 1 post-Boostrix® vaccination
|
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL), respectively.
|
At Month 1 post-Boostrix® vaccination
|
Number of Subjects With Anti-T Antibody Concentrations ≥ the Assay Cut-off Value
Time Frame: At Month 1 post-Boostrix® vaccination
|
The assay cut-off value was ≥ 1.0 IU/mL, as assessed by enzyme-linked immunosorbent assay (ELISA).
|
At Month 1 post-Boostrix® vaccination
|
Antibody Concentrations Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
Time Frame: At Month 1 post-Boostrix® vaccination
|
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
|
At Month 1 post-Boostrix® vaccination
|
Number of Subjects With Serum Haemagglutinin Inhibition (HI) Titers Against 3 Strains of Influenza
Time Frame: At Month 1 post-Fluarix® vaccination
|
The antibody titer cut-off value for the 3 influenza strains assessed (H1N1, H3N2 and B) was ≥ 1:40.
|
At Month 1 post-Fluarix® vaccination
|
Number of Seroconverted Subjects Against Influenza Antigens H1N1, H3N2, and B
Time Frame: At Month 1 post-Fluarix® vaccination
|
Seroconversion for HI antibodies is defined as: For initially seronegative subjects: post-vaccination antibody titer ≥ 1:40 at Month 1 post-Boostrix® vaccination; For initially seropositive subjects: antibody titer at Month 1≥ 4 fold the pre-vaccination antibody titer.
|
At Month 1 post-Fluarix® vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Seropositive Subjects With Anti-D Antibody Concentrations Above the Cut-off Value
Time Frame: At Month 1 post-Boostrix® vaccination
|
A seropositive subject was a subject whose antibody concentration was greater than or equal (≥) to the cut-off value of 1.0 IU/mL.
|
At Month 1 post-Boostrix® vaccination
|
Antibody Concentrations for Diphteria Toxoid (D) and Tetanus Toxoid (T)
Time Frame: At Day 0 and Month 1 post-Boostrix® vaccination
|
Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL).
|
At Day 0 and Month 1 post-Boostrix® vaccination
|
Antibody Concentrations for Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN)
Time Frame: At Day 0 and Month 1 post-Boostrix® vaccination
|
Anti-PT, anti-FHA and anti-PRN antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).
|
At Day 0 and Month 1 post-Boostrix® vaccination
|
Number of Subjects With Booster Response Against Diphteria Toxoid (D) and Tetanus Toxoid (T) Antigens
Time Frame: At Month 1 post-Boostrix® vaccination
|
Booster responses for anti-D and anti-T antibodies are defined as: For initially seronegative subjects [pre-vaccination concentration below (<) cut-off 0.1 IU/mL]: antibody concentrations at least four times the assay cut-off (post-vaccination concentration ≥ 0.4 IU/mL), one month after vaccination with Boostrix®; For initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with Boostrix®.
|
At Month 1 post-Boostrix® vaccination
|
Number of Subjects With Booster Response Against Pertussis Toxoid (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antigens
Time Frame: At Month 1 post-Boostrix® vaccination
|
Booster responses for anti-PT, anti-FHA and anti-PRN are defined as: For initially seronegative subjects (pre-vaccination concentration < cut-off of 5 EL.U/mL): antibody concentrations at least four times the cut-off (post-vaccination concentration ≥ 20 EL.U/mL), one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 5 EL.U/mL and < 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with Boostrix®; For initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with Boostrix®.
|
At Month 1 post-Boostrix® vaccination
|
Anti-H1N1, Anti-H3N2 and Anti-B Antibody Titers
Time Frame: At Month 1 post-Fluarix® vaccination
|
Anti-H1N1, anti-H3N2 and anti-B antibody titers are presented as geometric mean titers (GMTs).
|
At Month 1 post-Fluarix® vaccination
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Time Frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.
Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
|
During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Time Frame: During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
|
Assessed solicited general symptoms were fatigue, fever [defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], gastrointestinal (nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain, muscle aches and shivering.
Any = occurrence of the symptom regardless of intensity grade or relationship to the study vaccination.
Grade 3 symptom = symptom that prevented normal activity.
Grade 3 fever = fever > 39.0 °C.
Related = symptom assessed by the investigator as related to the vaccination.
Subjects from Boostrix+Fluarix Groups (19-64 YOA and ≥ 65 YOA) received only one vaccination dose (Boostrix® vaccine co-administered with Fluarix® vaccine), at Day 0.
|
During the 15-day (Day 0-14) period following each dose and across doses, up to 2 months
|
Number of Subjects With Any Unsolicited Adverse Events (AEs)
Time Frame: During the 31-day period (Day 0-30) following each vaccination, up to 2 months
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
During the 31-day period (Day 0-30) following each vaccination, up to 2 months
|
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: Throughout the whole study period (from Day 0 to Month 2)
|
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
Throughout the whole study period (from Day 0 to Month 2)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Weston WM, Friedland LR, Wu X, Howe B. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix((R))): results of two randomized trials. Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31.
- Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin. 2009 Dec;5(12):858-66. doi: 10.4161/hv.9961. Epub 2009 Dec 31.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2006
Primary Completion (Actual)
February 28, 2007
Study Completion (Actual)
February 28, 2007
Study Registration Dates
First Submitted
October 6, 2006
First Submitted That Met QC Criteria
October 6, 2006
First Posted (Estimate)
October 9, 2006
Study Record Updates
Last Update Posted (Actual)
June 10, 2019
Last Update Submitted That Met QC Criteria
June 6, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 106323
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Study Data/Documents
-
Clinical Study Report
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Dataset Specification
Information identifier: 106323Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tetanus
-
National Institute of Allergy and Infectious Diseases...Completed
-
Jiangsu Province Centers for Disease Control and...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedBacterial Infections | Group B StreptococcusUnited States
-
Changchun BCHT Biotechnology Co.The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaboratorsNot yet recruiting
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
EpicentreCompletedTetanus | Tetanus VaccineChad
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Tetanus | Diphtheria | Diphtheria Immunisation | Tetanus Immunisation | Clostridium Difficile ImmunisationMali
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDiphtheria, Tetanus and PertussisSpain
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownColorectal CancerUnited States, Canada
Clinical Trials on Fluarix®
-
National Institute of Allergy and Infectious Diseases...Completed
-
GlaxoSmithKlineCompleted
-
NanoPass Technologies LtdCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Center for Disease Prevention and Control of Beijing...Completed
-
GlaxoSmithKlineCompleted